AJP - Endocrinology and Metabolism, Vol 256, Issue 5 E640-E644, Copyright © 1989 by American Physiological Society

ARTICLES

Low oxygen selectively inhibits aldosterone secretion from bovine adrenocortical cells in vitro

H. Raff, D. L. Ball and T. L. Goodfriend
Department of Medicine, St. Luke's Medical Center, Medical College of Wisconsin, Milwaukee 53215.

Systemic hypoxia has been reported to inhibit selectively aldosterone secretion in vivo. The mechanism of this inhibition has not been elucidated. We hypothesized that decreased tissue PO2 directly inhibited aldosteronogenesis. To test this hypothesis, we exposed dispersed adrenocortical cells (90% glomerulosa/10% fasciculata) to decreased PO2 in vitro while simultaneously stimulating aldosterone secretion with angiotensin II, N6,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dibutyryl cAMP) adrenocorticotropic hormone (ACTH)-(1-24), or progesterone. Decreasing buffer PO2 from approximately 150 to approximately 85 Torr significantly inhibited basal and angiotensin II, cAMP, progesterone, and ACTH-stimulated aldosterone secretion at all doses of secretagogue. Inhibition was largest for angiotensin II (55 +/- 9% inhibition at 1 microM) and cAMP (54 +/- 8% at 3 mM) and lowest for ACTH (24% at 100 nM) and basal aldosterone secretion (31 +/- 7%). This inhibition was reversed by returning the buffer PO2 to 150 Torr. Cortisol secretion was not significantly inhibited by decreased buffer PO2. We conclude that decreased buffer PO2 significantly inhibits aldosterone secretion in vitro, and this inhibition is reversible and specific. Hypoxia-induced inhibition of aldosterone secretion in vivo may be caused, at least in part, by a direct effect of low tissue PO2 within the adrenal cortex.

This article has been cited by other articles:

				H. Raff, E. D. Bruder, and the St. Luke's Medical Center Adrenal Tumor Study Steroidogenesis in human aldosterone-secreting adenomas and adrenal hyperplasias: effects of hypoxia in vitro Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E199 - E203. [Abstract] [Full Text] [PDF]

				D. R. Woods, A. J. Pollard, D. J. Collier, Y. Jamshidi, V. Vassiliou, E. Hawe, S. E. Humphries, and H. E. Montgomery Insertion/Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene and Arterial Oxygen Saturation at High Altitude Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 362 - 366. [Abstract] [Full Text] [PDF]

				E. T. Morgan, V. Ullrich, A. Daiber, P. Schmidt, N. Takaya, H. Shoun, J. C. McGiff, A. Oyekan, C. J. Hanke, W. B. Campbell, et al. Cytochromes P450 and Flavin Monooxygenases---Targets and Sources of Nitric Oxide Drug Metab. Dispos., November 1, 2001; 29(11): 1366 - 1376. [Abstract] [Full Text] [PDF]

				C. J. Hanke and W. B. Campbell Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen Am J Physiol Endocrinol Metab, October 1, 2000; 279(4): E846 - E854. [Abstract] [Full Text] [PDF]

				C. De Angelis and G. T. Haupert Jr. Hypoxia triggers release of an endogenous inhibitor of Na+-K+-ATPase from midbrain and adrenal Am J Physiol Renal Physiol, January 1, 1998; 274(1): F182 - F188. [Abstract] [Full Text] [PDF]

				M. H. Bestle, N. V. Olsen, T. D. Poulsen, R. Roach, N. Fogh-Andersen, and P. Bie Prolonged hypobaric hypoxemia attenuates vasopressin secretion and renal response to osmostimulation in men J Appl Physiol, May 1, 2002; 92(5): 1911 - 1922. [Abstract] [Full Text] [PDF]